Alendronate is superior to alfacalcidol in preventing glucocorticoid-induced bone loss

N Engl J Med. 2006 Aug 17;355(7):675-84

Discontinuing alendronate after 5 years of treatment, does it affect fracture risk?

JAMA. 2006 Dec 27;296(24):2927-38.

Alendronate treatment for fibrous dysplasia, a rare skeletal disorder

J Clin Endocrinol Metab. 2014 Nov;99(11):4133-40.

Effectiveness of Alendronate versus Alfacalcidol in maintaining bone mineral density

Journal of Bone and Joint Surgery American; 2011; 93(A); 1203-1209

Denosumab increases bone mass but does not reduce fracture risk compared to alendronate

Int J Clin Pract. 2012 Apr;66(4):399-408. doi: 10.1111/j.1742-1241.2011.02806.x. Epub 2012 Feb 7

Alendronate & zoledronate both reduce hip and vertebral fracture risk compared to placebo

Gynecol Endocrinol. 2013 Dec;29(12):1005-14. doi: 10.3109/09513590.2013.813468. Epub 2013 Sep 25

Combined parathyroid hormone+alendronate therapy versus PTH monotherpy for osteoporosis

J Invest Surg. 2015 Dec;28(6):309-16

Bisphosphonates in revision THA ineffective in altering pseudomembrane cytokine expression

J Arthroplasty. 2010 Sep;25(6):958-63

The role of alendronate in osteoporosis patients undergoing PLIF

J Neurosurg Spine. 2011 Apr;14(4):500-7. doi: 10.3171/2010.11.SPINE10245. Epub 2011 Jan 28

The effect of alendronate post-TKA on bone mineral density and clinical outcome

Bone Joint J. 2015 Mar;97-B(3):337-45

Alendronate is an effective way of increasing BMD and reducing bone turnover

J Int Med Res. 2011;39(1):302-10

Denosumab is superior to alendronate for improving cortical bone porosity post-menopause

Bone. 2014 Feb;59:173-9. doi: 10.1016/j.bone.2013.11.016. Epub 2013 Nov 22.

Etidronate, alendronate, and reisendronate significantly reduce the risk of hip fracture

Curr Med Res Opin. 2011 Jun;27(6):1141-8. doi: 10.1185/03007995.2011.570747. Epub 2011 Apr 1

Adherence to weekly oral BP therapy versus quarterly IV BP therapy at varying health literacy level

J Bone Miner Metab. 2018 Sep;36(5):589-595. doi: 10.1007/s00774-017-0867-y

WCO-IOF: Changes with QCT, DXA, and TBS between denosumab, alendronate, & placebo

The effect of eldecalcitol on balence and strength in women with osteoporosis

J Bone Miner Metab. 2016 Sep;34(5):547-54

Improved bone mineral density up to 12 months with a 6-month oral alendronate intervention

J Bone Joint Surg Am. 2006 Feb;88(2):267-72

Teriparatide increases BMD in patients with glucocorticoid-Induced osteoporosis

N Engl J Med. 2007 Nov 15;357(20):2028-39

WCO-IOF 2016: Alfacalcidol (Vit D analogue) vs. cholecalciferol (Vit D) for osteoporosis

Comparison of risedronate, alendronate, zoledronate, and ibandronate in those with low BMD

Bone. 2016 Aug;89:52-8